Risdiplam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Risdiplam: From Spinal Muscular Atrophy to Acne
One-Sentence Summary
Risdiplam (Evrysdi) is an oral SMN2 splicing modifier marketed in Australia. The data compiled for this report do not include an approved indication text, but the drug is known as a treatment for spinal muscular atrophy (SMA). The TxGNN model predicts it may be effective for acne, with a high score but no clinical trials and no publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the data compiled for this report (the ARTG entry has no indication text) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 0.9945 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Risdiplam is generally described as an SMN2 splicing modifier, which promotes inclusion of exon 7 in SMN2 transcripts. Its efficacy has been established in its original neuromuscular indication, but no mechanistic link to acne has been demonstrated.
The prediction is computational only. One speculative hypothesis is an off-target effect on RNA splicing in sebaceous or epithelial tissue, but nothing in the data supports it. The relationship between the original and new indication is not yet characterised.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12606L | Evrysdi | Powder for oral solution 750 micrograms per mL, 80 mL | Not stated in the data compiled |
Safety Considerations
- Drug Interactions (2 moderate-level interactions identified):
- Metformin (Moderate)
- Methylnaltrexone (Moderate)
Warning and contraindication text was not available. Please refer to the TGA-approved Product Information (PI) for full safety information. Animal studies have reported retinal toxicity, which is relevant to any new use.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (Evidence Level L5). There are no registered trials, no publications, and no validated mechanistic link between risdiplam and acne. The original indication text and the safety labelling were also unavailable.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) to assess any plausible link to acne
- Approved indication text and PI warnings and contraindications from the TGA-approved Product Information
- Preclinical or mechanistic studies testing splicing modulation in sebaceous or epithelial tissue
- A review of the safety profile (including skin and ocular findings) against the acne population, which is typically younger and may be long-term treated
- Comparison with established acne therapies to define a realistic unmet need
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.